39
Participants
Start Date
October 7, 2020
Primary Completion Date
June 8, 2021
Study Completion Date
June 22, 2021
Furosemide (loop diuretic) Tablets
Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not \>320mg/day for the 2nd \& 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.
Carolina Dialysis - Pittsboro, Pittsboro
Carolina Dialysis - Sanford, Sanford
Carolina Dialysis - Lee County, Sanford
Carolina Dialysis - Siler City, Siler City
Carolina Dialysis - Carrboro, Carrboro
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
University of North Carolina, Chapel Hill
OTHER